| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CM |
| Uniprot No | Q8N6K0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-151aa |
| 氨基酸序列 | MEYVLEVKNSPRHLLKQFTVCDVPLYDICDYNVSRDRCQELGCCFYEGVCYKKAVPIYIHVFSALIVIIAGAFVITIIYRVIQESRKEKAIPVDVALPQKSSEKAELASSSSKLGLKPASPGPPSAGPSMKSDEDKDDVTGTITEAEETED |
| 预测分子量 | 16,6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于不同领域可能涉及的“CM重组蛋白”的参考文献示例。由于“CM”的指代不明确(可能为细胞膜、巨细胞病毒或条件培养基等)，以下提供不同方向的假设性示例，并标注了可能的背景说明：
---
### 示例1(假设CM指**细胞膜相关蛋白**)
**文献名称**：*"High-yield production of recombinant caveolin-1 in mammalian cells for membrane protein studies"*
**作者**：Zhang, L. et al.
**摘要**：研究报道了在哺乳动物细胞中高效表达与纯化重组caveolin-1(一种细胞膜穴样凹陷标志蛋白)的方法，验证了其与胆固醇结合的功能特性，为膜蛋白相互作用研究提供工具。
---
### 示例2(假设CM指**巨细胞病毒(Cytomegalovirus, CMV)**)
**文献名称**：*"Recombinant CMV glycoprotein B vaccine elicits potent neutralizing antibodies in animal models"*
**作者**：Wang, Q. et al.
**摘要**：通过杆状病毒系统表达重组CMV糖蛋白B(gB)，并证明其在小鼠模型中诱导强效中和抗体，为CMV疫苗开发奠定基础。
---
### 示例3(假设CM指**条件培养基(Conditioned Medium)中的应用**)
**文献名称**：*"Recombinant TGF-β1 in cancer-associated fibroblast CM promotes tumor invasion"*
**作者**：Kim, H. et al.
**摘要**：探讨了肿瘤相关成纤维细胞条件培养基(CM)中重组TGF-β1对癌细胞侵袭的调控作用，揭示了其在肿瘤微环境中的关键机制。
---
### 示例4(结构生物学方向)
**文献名称**：*"Crystal structure of recombinant calmodulin (CM) bound to calcium ions"*
**作者**：Chen, X. et al.
**摘要**：解析了钙调蛋白(Calmodulin, CaM)重组体的晶体结构，阐明其钙离子结合后的构象变化及下游信号传导机制。
---
**说明**：
1. 以上文献为示例性质，具体研究方向需根据“CM”的实际定义调整。
2. 若需真实文献，建议补充“CM”的全称或研究背景(如疾病、分子功能等)，以便精准检索。
**Background of CM Recombinant Proteins**
CM recombinant proteins, often referring to chimeric or composite membrane proteins, are engineered biomolecules designed by combining genetic elements from different sources to achieve specific structural or functional properties. These proteins are typically generated using recombinant DNA technology, where target gene sequences are inserted into expression vectors and expressed in host systems like *E. coli*, yeast, or mammalian cells. The "CM" designation may denote applications in cell membrane studies, vaccine development, or therapeutic interventions, depending on the context.
A key motivation for developing CM recombinant proteins lies in their ability to mimic natural membrane-associated proteins, such as viral envelope proteins or cell surface receptors, which are critical for pathogen-host interactions or cellular signaling. For example, in vaccine design, CM proteins may incorporate antigenic domains from pathogens (e.g., SARS-CoV-2 spike protein) fused with stabilizing domains to enhance immunogenicity and stability. This approach has been pivotal in creating subunit vaccines and diagnostic tools.
Production challenges include ensuring proper folding, post-translational modifications (e.g., glycosylation), and membrane integration, often requiring mammalian expression systems. Advances in structural biology and bioinformatics have enabled precise engineering of these proteins, improving yield and functionality.
CM recombinant proteins are widely used in biomedical research, drug discovery, and biopharmaceuticals. Their versatility supports studies on protein-protein interactions, antibody development, and targeted therapies. Despite technical hurdles, ongoing innovations in expression systems and purification methods continue to expand their applications, cementing their role in modern biotechnology and medicine.
×
